Your browser doesn't support javascript.
loading
DNA double-strand break-free CRISPR interference delays Huntington's disease progression in mice.
Seo, Jung Hwa; Shin, Jeong Hong; Lee, Junwon; Kim, Daesik; Hwang, Hye-Yeon; Nam, Bae-Geun; Lee, Jinu; Kim, Hyongbum Henry; Cho, Sung-Rae.
Afiliação
  • Seo JH; Department and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Shin JH; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Lee J; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Kim D; Department of Pharmacology, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Hwang HY; Department of Ophthalmology, Institute of Vision Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Nam BG; Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
  • Lee J; Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
  • Kim HH; Department and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Cho SR; Graduate Program of Biomedical Engineering, Yonsei University College of Medicine, Seoul, Republic of Korea.
Commun Biol ; 6(1): 466, 2023 04 28.
Article em En | MEDLINE | ID: mdl-37117485
ABSTRACT
Huntington's disease (HD) is caused by a CAG repeat expansion in the huntingtin (HTT) gene. CRISPR-Cas9 nuclease causes double-strand breaks (DSBs) in the targeted DNA that induces toxicity, whereas CRISPR interference (CRISPRi) using dead Cas9 (dCas9) suppresses the target gene expression without DSBs. Delivery of dCas9-sgRNA targeting CAG repeat region does not damage the targeted DNA in HEK293T cells containing CAG repeats. When this study investigates whether CRISPRi can suppress mutant HTT (mHTT), CRISPRi results in reduced expression of mHTT with relative preservation of the wild-type HTT in human HD fibroblasts. Although both dCas9 and Cas9 treatments reduce mHTT by sgRNA targeting the CAG repeat region, CRISPRi delays behavioral deterioration and protects striatal neurons against cell death in HD mice. Collectively, CRISPRi can delay disease progression by suppressing mHtt, suggesting DNA DSB-free CRISPRi is a potential therapy for HD that can compensate for the shortcoming of CRISPR-Cas9 nuclease.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_alzheimer_other_dementias / 6_mental_health_behavioral_disorders Assunto principal: Doença de Huntington Limite: Animals / Humans Idioma: En Revista: Commun Biol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_alzheimer_other_dementias / 6_mental_health_behavioral_disorders Assunto principal: Doença de Huntington Limite: Animals / Humans Idioma: En Revista: Commun Biol Ano de publicação: 2023 Tipo de documento: Article
...